Aether Industri. Q1 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- Anticipated robust growth in FY24, though raw material price crash delayed momentum to Q3-Q4 (Page 10).
- Expected recovery and growth in agrochemical sector demand from Q3-Q4 after current destocking phase (Page 9, 18-19).
- Site 3 maturity expected to generate approx. Rs. 400 crores revenue over next 2 years (Page 9-10).
- Launch of new products in Site 3+, Site 3++, Site 4, and Site 5 to drive growth in upcoming years (Page 5).
- Oil field services contract starting contribution from Q4 FY24, full impact in FY25, with 16,000 MT/year volume and Rs. 300+ crores revenue potential (Page 4, 12).
- Diversification across pharma, agrochemical, material science, and oil & gas sectors to balance portfolio and stimulate growth (Page 18-19).
- Long-term focus on R&D pipeline and innovation to sustain new product launches and market expansion (Pages 5, 19).
See what Aether Industri. management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- The company successfully raised Rs. 750 crores through Qualified Institutional Placement (QIP) by issuing 80.12 lakh equity shares to 36 qualified institutional buyers.
- The funds from this QIP will be deployed for CAPEX for Site 3 and Site 5, working capital requirements, and general corporate purposes.
- There is no mention of any new or upcoming fundraising through debt or equity beyond this QIP in the provided pages.
- The company is currently focusing on utilizing this raised capital for expansion and operational needs.
See what Aether Industri. management said on order book — free account, 30 seconds.
Capex plans
Yes- Raised Rs. 750 crores through Qualified Institutional Placement (QIP) for CAPEX on Site 3, Site 5, working capital, and general corporate purposes.
- Site 5: Planned CAPEX of Rs. 330 crores for large-scale and contractual exclusive manufacturing; asset turn targeted at 2X.
- Construction underway for Site 3++ with 3 new molecules scheduled to launch in next 12-14 months.
- Site 4 project initiated for strategic supply agreement with a major US oil field services company; commissioning expected to start contributing from Q4 FY24, full contribution in FY25.
- Investment focus on expanding R&D infrastructure: plans to double R&D building and manpower within next 1-2 years.
- Strategic acquisitions under preliminary discussion in US and Europe to enhance R&D capabilities and footprint, no finalization yet.
- Licensing agreement with Saudi Aramco Technologies finalized for commercializing sustainable converge polyols technology.
Track Aether Industri. — get its next earnings analysis in your feed
Margin guidance
Category 3- Q2 and Q3 expected to be challenging quarters due to agro sector slowdown and inventory destocking; recovery anticipated in Q3 and Q4.
- Management optimistic about normalization and growth in Q3-Q4, targeting better momentum for the year-end.
- Revenue target of around INR 1000 crores for FY24 is still expected, though some delay possible due to market conditions.
- The launch of new molecules at Site 3 and Site 3++, along with large-scale manufacturing and contractual services, to drive future revenue growth.
- The oil field services business, expected to contribute from Q4 FY24 and FY25, has strong revenue potential (over Rs. 300 crores/year) with EBITDA margins around 28-30%.
- EBITDA margins maintained around 29% with focus on high-value product mix to protect profitability despite pricing pressure.
- R&D pipeline and diversification into material sciences, flavor & fragrance, oil & gas sectors underpin long-term growth.
- Cost advantages via solar power plant and reduced utility costs expected to support margins.
Order book
- The company has signed a Letter of Intent (LOI) with one of the top three global oil field services companies in the US.
- This LOI includes four strategic products with a combined volume of approximately 16,000 metric tons per year, with expected revenues north of Rs. 300 crores annually starting fiscal 2025.
- Partial contributions from this orderbook are expected in the last quarter of the current fiscal year.
- The company has also launched multiple new products across various sites, including Site 3 and Site 3++, with a pipeline expected to contribute significantly over the next 1-2 years.
- Site 3 at maturity is projected to generate around Rs. 400 crores in revenue.
- Contract renewals and new product launches are anticipated to pick up in Q2-Q4 of the current fiscal year, with Q2 remaining challenging.
- Discussions on small acquisitions and expansion of R&D capabilities are ongoing but not finalized.
How does Aether Industri. rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Aether Industri. rank in Chemicals & Petrochemicals?
Compare Aether Industri. against every Chemicals & Petrochemicals company (Q1 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Aether Industri.'s management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Ch. (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
- Deepak Fertilis. (Q1 FY27)
Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…